The application of adjuvant autologous antravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: a multicenter, randomized trial

The application of adjuvant autologous antravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: a multicenter, randomized trial

<p>Abstract</p> <p>Introduction</p> <p>While adjuvant immunotherapy with Bacille Calmette Guérin (BCG) is effective in non-muscle-invasive bladder cancer (BC), adverse events (AEs) are considerable. Monocyte-derived activated killer cells (MAK) are discussed as essentia...

Full description

Bibliographic Details
Main Authors: Kiss Tamas, Thüroff Joachim W, Romics Imre, Grimm Marc O, Zsolt Domján, Szabo Zoltán, Kisbenedek Laszlo, Jimenz-Cruz Fernando J, Chapado Manuel S, Benoit Gerard, Kondas Jozsef, Denzinger Stefan, Thiounn Nicolas, Burger Maximilian, Tombal Bertrand, Wirth Manfred, Munsell Marc, Mills Bonnie, Koh Tung, Sherman Jeff
Format: Article
Language:English
Published: BMC 2010-06-01
Series:Journal of Translational Medicine
Online Access:http://www.translational-medicine.com/content/8/1/54

Internet

http://www.translational-medicine.com/content/8/1/54

Similar Items